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Abstract 
Purpose: To improve the sensitivity and specificity of spectrophotometric 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase activity assay. 
Methods: Spectrophotometric HMG-CoA reductase detection in male Wistar rat liver microsomes was 
optimized by applying different conditions, such as reaction buffer pH, NADPH and protein 
concentration, and preincubation and reaction times. The optimal set of conditions was validated using 
HMG-CoA reductase inhibitors, namely, pravastatin, fluvastatin, and rosuvastatin. IC50 was calculated 
and compared with that of a radiochemical assay. Ginkgo biloba extract’s (GBE50) inhibitory effect on 
HMG-CoA reductase activity was evaluated using the optimized spectrophotometric protocol. 
Results: The optimum assay conditions were as follows: reaction buffer pH 7.0, 100 µM NADPH, 50 
µM HMG-CoA, and 200 µg/mL microsomal protein. The preincubation and reaction times were 20 and 
60 min, respectively, at 37 ºC. The IC50 of pravastatin, fluvastatin, and rosuvastatin under the optimum 
condition was 0.026, 0.015, and 0.007 µM while for radioisotope assay, it was 0.034, 0.049 and 0.0119 
µM, respectively. GBE50 significantly inhibited HMG-CoA reductase activity in a concentration-
dependent manner (p < 0.05). 
Conclusion: These results suggest that HMG-CoA reductase activity can be detected using the 
improved spectrophotometric assay. This assay can facilitate the discovery and development of new 
HMG-CoA reductase inhibitors in vitro.   
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Mevalonic acid (MVA) is an important 
biochemical intermediate in cholesterol 
synthesis. High circulating cholesterol levels may 
induce atherosclerosis, which contributes to the 
occurrence of cardiovascular and 
cerebrovascular disorders and diseases, such as 
hypertension, coronary heart disease, 
thrombosis, and cerebral hemorrhage [1].  
 
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase is the rate-limiting enzyme in the 
MVA to cholesterol biotransformation pathway. 
Accordingly, it plays a significant role in 
cholesterol homeostasis [2]. Although methods to 
determine HMG-CoA reductase mRNA and 
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protein expression in various regulatory 
mechanisms are well established [3], a sensitive, 
economical HMG-CoA reductase activity assay 
has not been developed. HMG-CoA reductase 
activity is conventionally assayed using elaborate 
radiochemical techniques [4], chromatographic 
techniques coupled with mass spectrometry 
(LC/MS) [5], or spectrophotometrically monitoring 
the decrease in the cofactor NADPH absorbance 
at 340 nm [6].  
 
The radiolabeled assay is limited for several 
reasons, including the use of radioactive 
substances, the complicated procedure, the 
potential for radioactive contamination, and the 
high cost. LC/MS requires advanced and 
expensive instruments, which limits its use as a 
routine laboratory technique. Compared with 
these methods, spectrophotometry is rapid and 
simple. There is no need to separate the 
products or handle radioactive materials. 
Moreover, spectrophotometers are standard 
laboratory equipment, making them easily 
accessible. However, spectrophotometric assays 
do have some disadvantages. They are subject 
to high background NADPH hydrolysis if the 
protein sample comes from whole cells or 
purified organelles, and protein purification is 
complicated and expensive. If an optimized 
spectrophotometric assay that is both sensitive 
and simple were developed, it would be of great 
importance in basic and pharmacological 
research on cholesterol metabolism.  
 
HMG-CoA reductase inhibitors effectively reduce 
cholesterol biosynthesis, which makes them 
valuable hypolipidemic agents and the drugs of 
choice for atherosclerosis. Thus, a large number 
of studies investigating HMG-CoA reductase 
inhibitors are underway to identify candidate 
drugs for treating hypercholesterolemic disorders 
[7].  
 
The objective of this study was to develop an 
improved spectrophotometric HMG-CoA 
reductase activity assay by optimizing key factors 
in the reaction condition. Furthermore, we 
evaluated the HMG-CoA reductase inhibitory 
effects of Ginkgo biloba extract (GBE50), which 
has been implicated in cholesterol metabolism 
modulation [8,9], using the improved 




Chemicals and materials 
 
Colestyramine was purchased from Life-care 
Pharmaceutical Co. (Nanjing, China), and 
NADPH was from Beyotime Biotechnology Co. 
(Shanghai, China). HMG-CoA, Pravastatin, 
Fluvastatin and Rosuvastain were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). [14C]-
HMG-CoA and [14C]-Mevalonolactone (2.14 
GBq/mmoL) were obtained from GE Healthcare 
Life Sciences (Buckinghamshire, UK). GBE50 
was purchased from XingLing Pharmaceutical 
Co. (Shanghai, China). All other chemicals and 




The animal studies were approved by Ethics 
Committee of Wuhan University, and the study 
protocol was in accordance with the guidelines 
for the Care and Use of Laboratory Animals of 
the Chinese Animal Welfare Committee. Male 
Wistar rats (220 - 250 g) were obtained from the 
Experimental Center of Hubei Medical Scientific 
Academy (China, no. 2006-0005). The animals 
were housed in a light-controlled room with the 
dark period from 7:00 AM to 7:00 PM, and fed ad 
libitum with 2 % cholestyramine-supplemented 
powdered diet for 6 days to achieve maximal 
liver HMG-CoA reductase activity [10]. The 
animals were anesthetized using isoflurane and 
sacrificed by decapitation at 10:00 AM on the 
sixth day, and the liver were isolated, weighed, 
and immediately stored at -80 °C until 
subsequent analysis.   
 
Liver microsome preparation  
 
Rats liver microsomes were prepared by 
homogenization and differential centrifugation 
using established protocols [11]. In brief, the 
tissues were homogenized in three-fold volume 
ice-cold homogenization buffer A (100 mM 
sucrose, 50 mM KCl, 40 mM potassium 
phosphate, 30 mM potassium EDTA, pH 7.2) 
with a motor-driven, glass-Teflon Potter-
Elvehjem homogenizer (JingKe Chemical Co., 
Shanghai). The homogenate was centrifuged for 
15 min at 12,000 × g, the supernatant was 
removed and centrifuged again for 15 min at 
12,000 × g, and the resultant supernatant was 
centrifuged for 60 min at 100,000 × g. The pellets 
were resuspended in buffer A and centrifuged at 
100,000 × g for 60 min. Following that, the 
pellets were resuspended in buffer B (buffer A 
plus 10 mM dithiothreitol) using a hand-driven, 
all-glass Potter-Elvehjem homogenizer to 
prepare microsomal suspension. All of the 
operations were performed at 4 °C. The final 
suspension was stored at -20 °C. 
 
HMG-CoA reductase solubilization 
 
The Beg ZH method was used to solubilize the 
enzyme [11]. The microsomal suspension was 
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thawed at 37 °C water and an equal volume of 
buffer B supplemented with 50 % glycerol and 
preheated to 37 °C was added. The mixture was 
homogenized thoroughly with a hand-driven, all 
glass Potter-Elvehjem homogenizer and 
incubated at 37 °C for 60 min.  The suspension 
was diluted three-fold with buffer B, 
homogenized again, and then centrifuged at 
100,000 × g for 60 min at 25 °C. The supernatant 
containing solubilized HMG-CoA reductase was 
used for the activity assay. The supernatant 
protein concentration was determined using the 
Bradford method [12], and the protein 
concentration was adjusted to 1 mg/mL. 
 
Spectrophotometric HMG-CoA reductase 
activity assay 
 
The HMG-CoA reductase activity was 
determined spectrophotometrically using 
previously published protocols [7,13] with some 
modifications. Briefly, the total reaction volume 
was 1 mL. The reaction was preincubated at 37 
ºC. Both the microsomal protein (total protein 
concentration 200 µg/mL) and 100 µM NADPH 
were added to buffer C (0.2 M KCl, 0.16 M 
potassium phosphate, 0.004 M EDTA, and 0.01 
M dithiothreitol). The reaction was initiated with 
50 µM HMG-CoA and was allowed to proceed for 
60 min. When the reaction finished, the optical 
density at 340nm was measured using a UV-
1601 spectrophotometer (Shimadzu, Japan). 
One unit of enzyme activity was defined as the 
amount of NADPH consumed by 1 mg enzyme 
per minute. The system was validated via 
inhibition studies using three HMG-CoA 
reductase inhibitors: pravastatin, fluvastatin and 
rosuvastatin.  
 
Radiochemical HMG-CoA reductase activity 
assay  
 
To validate the optimized spectrophotometric 
assay, an adaptation of the radiochemical 
method described previously [14] was used to 
compare HMG-CoA reductase activity inhibition 
by pravastatin, fluvastatin and rosuvastatin 
(positive controls). A 120-µL reaction volume 
consisted of the microsomal protein and 500 
nmoL of NADPH (dissolved in the reaction buffer 
containing 0.1 M of triethanolamine and 10 mM 
of EDTA). The reaction was preincubated at 37 
ºC for 5 min. Then the drug inhibition was 
evaluated using different concentrations: 
pravastatin (1.3, 12.9, and 129 µg/L), fluvastatin 
(0.7, 7.7, and 77.4 µg/L) and rosuvastatin (0.3, 
3.2, and 32.3 µg/L).  
 
The reaction was initiated with 5.17 nmoL of 
[14C]-HMG-CoA. The reaction proceeded for 15 
min at 37 ºC and terminated by the addition of 30 
µL of 6 M HCl. The resultant mixture was 
incubated at 37 ºC for another 15 min to allow 
the MVA to convert to mevalonolactone. The 
incubation mixture was centrifuged at 10,000 g 
for 5 min, and the supernatant was directly 
spotted on a Silica Gel 60 F254 TLC plate 
(Merck, Germany). The plate was developed in 
benzene:acetone (1:1, v/v).  
 
Finally, the Rf 0.5-0.9 region was removed by 
scraping using a clean razor blade, and the [14C] 
radioactivity determined using a liquid scintillation 
counter. [14C]-mevalonolactone was used as a 
standard. The 50 % inhibitory concentration 
(IC50) of the three drugs was calculated using the 
Statistical Package for Social Sciences (SPSS 
17.5) software package. 
 
Inhibitory effect of GBE50 on HMG-CoA 
reductase activity 
 
GBE50’s inhibitory effect in different 
concentrations (32.26, 322.6, and 3226 µg/L) on 
HMG-CoA reductase activity was tested using 
the optimized spectrophotometric assay.  
 
Statistical analysis  
 
The data were expressed as mean ± SD. SPSS 
17.5 software was used for data analysis. 
Analysis of variance (one-way ANOVA) was 
used to compare the means of different groups. 




Reaction buffer pH and preincubation and 
reaction time duration 
 
The pH of the spectrophotometric reaction buffer, 
buffer C, was adjusted to five different values: 
6.0, 6.5, 7.0, 7.5, and 8.0 and the activity was 
assayed. The activity increased initially but 
decreased when the reaction buffer pH value 
was greater than 7.0. Accordingly, the optimal 
reaction buffer pH for maximum reductase 
activity was 7.0 (Fig 1A, p < 0.05 vs. pH 6.5). 
 
The reaction mixtures with 200 µg microsomal 
protein were preincubated with 100 µM NADPH 
at 37 ºC for 0 – 40 min prior to the addition of 50 
µM HMG-CoA (Fig. 1B). The reaction proceeded 
for 40 min at 37 ºC. HMG-CoA reductase activity 
slightly increased with increased preincubation 
time then decreased. Peak activity occurred at a 
preincubation time of approximately 20 min (p < 
0.05 vs. 0 min).  
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The reductase activity increased linearly with 
increased reaction time until 60 min and then 
plateaued. Therefore, the optimal reaction time 
was 60 min (Fig 1C, p < 0.05 vs. 50 min). 
 
NADPH and microsomal protein 
concentration  
 
There was an approximately linear increase in 
reductase activity with increased microsomal 
protein concentrations, and a microsomal protein 
concentration of 200 µg/mL was an appropriate 
concentration to obtain higher HMG-CoA 
reductase activity (Fig 2B, p < 0.05 vs. 50 µg/L). 
 
Validation and application of the optimized 
assay 
 
Assay of three known HMG-CoA reductase 
inhibitors  
 
All the three drugs, pravastatin, fluvastatin and 
rosuvastatin, inhibited HMG-CoA reductase 
activity in a concentration-dependent manner, 
and the linear correlations (r values) were 0.999 
(Fig 3A), 0.98 (Fig 3B) and 0.87 (Fig 3C), 
respectively. The IC50 of pravastatin, fluvastatin 





Figure 1: Effects of different reaction buffer pH (A), preincubation duration (B) and reaction time (C) on 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity. Data are presented as mean ± SD, n=5; p 
 0.05 vs control group 
 
 
Figure 2: Effects of NADPH concentration (A) and microsomal protein concentration (B) on HMG-CoA reductase 
activity. Data points are mean ± SD (n = 5); p  0.05 vs control group 
 
 
Figure 3: Pravastatin (A), fluvastatin (B), and rosuvastatin (C) inhibition of HMG-CoA reductase activity detected 
using the optimized spectrophotometric assay. Data points are mean ± SD (n = 5); p  0.05 vs. control group 
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Figure 4: Inhibitory effect of pravastatin (A), fluvastatin (B), and rosuvastatin (C) inhibition of HMG-CoA 
reductase activity detected using a radioisotope assay. Data points are expressed as mean ± SD (n = 5); p  
0.05 vs. control group (pravastatin 1.3 g/L, fluvastatin 0.7 g/L, and rosuvastatin 0.3 g/L) 
 
Figure 5: Effect of Ginkgo biloba extract (GBE50) on 
HMG-CoA reductase activity. Data points are 
expressed as mean ± SD (n = 5); p  0.05 vs control 
group 
 
We also evaluated the three inhibitors using a 
radioisotope assay. There was a linear 
relationship between HMG-CoA reductase 
inhibition and drug concentration for all three 
known inhibitors, and the r values were 0.985, 
0.976, and 0.999, respectively (Fig 4). The IC50s 
of pravastatin, fluvastatin, and rosuvastatin from 
the radioisotope assay were as follows: 0.0343, 
0.0485, and 0.0119 µM, respectively. 
 
Application of the optimal spectropho-
tometric assay  
 
GBE50 inhibited HMG-CoA reductase activity in 





Over the years, the major shortcomings of the 
spectrophotometric HMG-CoA reductase activity 
assay have been identified. Direct 
spectrophotometric NADPH oxidation 
determination is readily subject to interference by 
other NADPH-expending reactions, and these 
non-specific reactions produce excess 
background making the measurements 
inaccurate [15]. Rat liver microsomes, the 
enzyme source in this study, contain complex 
NADPH-dependent enzymatic systems that 
consist of HMG-CoA and others (e.g. HMG-CoA 
lyase) [16]. Therefore, it is important to improve 
the spectrophotometric accuracy by eliminating 
non-specific NADPH consumption that not 
derived from HMG-CoA. Previous studies 
obtained high HMG-CoA reductase activity using 
a complicated and expensive purification 
technique [17]. There is still a need for a simple 
and rapid HMG-CoA reductase activity assay. 
 
In this study, we optimized several reaction 
variables including the reaction buffer pH, the 
preincubation and reaction duration, and 
substrate and microsomal protein concentrations. 




First, we adjusted each variable independently 
while keeping all others fixed to achieve the 
highest HMG-CoA reductase activity. Once the 
optimized variable was determined, it would be 
applied to the subsequent reaction system 
optimization experiments.  
 
Our results showed that the optimal 
spectrophotometric HMG-CoA reductase activity 
assay conditions are as follows: reaction buffer 
pH 7.0, containing 100 µM NADPH and 200 
µg/mL microsomal protein, incubating the protein 
and NADPH for 20 min at 37 ºC prior to 50 µM 
HMG-CoA addition, and reacting for 60 min at 37 
ºC. High HMG-CoA reductase activity was 
obtained in these conditions. The HMG-CoA 
reductase specific activity was approximately 160 
µmoL NADPH oxidized/min•mg microsomal 
protein under the optimal condition.  
 
To validate this spectrophotometric assay 
system, we compared the kinetic results from our 
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optimized spectrophotometric assay with a 
radioisotope assay using three known HMG-CoA 
reductase inhibitors (pravastatin, fluvastatin and 
rosuvastatin). Our results showed that the IC50s 
of the known inhibitors calculated using the 
improved spectrophotometric assay are the 
same order of magnitude as those obtained 
using a radioisotope assay. The GBE50 inhibition 
of HMG-CoA reductase activity was evaluated 
using the optimal spectrophotometric assay. 
GBE50 demonstrated concentration-dependent 
inhibition of HMG-CoA reductase activity. This 
result is consistent with our previously study 
using a radioisotope assay [18]. 
 
Recently, a HMG-CoA reductase assay kit 
became commercially available (Sigma-Aldrich, 
St. Louis, MO, USA). The kit provides the human 
enzyme catalytic domain (HMGR; recombinant 
GST fusion protein expressed in E. coli), and it 
has been used in some studies [19]. The assay 
also spectrophotometrically measures the 
absorbance decrease at 340 nm, which 
represents NADPH oxidation by HMGR in the 
presence of the HMG-CoA substrate.  
 
However, according to the manufacturer’s 
documentation, the kit is only designed to screen 
for different inhibitors/activators of the purified 
catalytic subunit in vitro (http://www.sigma 
aldrich.com/china-mainland/zh/technical-docum 
ents/articles/biofiles/hmg-coa-reductase.html#M 
aterials). In vivo, HMG-CoA reductase activity is 
controlled through synthesis, degradation, and 
phosphorylation in order to maintain the 
appropriate mevalonate-derived product 
concentrations. This regulation plays a vital role 
in hepatic lipid metabolism, especially for 
cholesterol metabolic pathway. Therefore, an 
accurate HMG-CoA reductase activity assay 
using whole protein from animals or tissues is 
imperative for investigating cholesterol 
homeostasis disturbance mechanisms and 
associated diseases, such as hyperchole-
sterolemia.  
 
Unfortunately, a well-developed, simple, rapid, 
and accurate method for assaying HMG-CoA 
reductase activity in these types of samples has 
not yet been achieved. For example, Rao et al 
described an indirect HMG-CoA reductase 
activity assessment in liver tissue [20], which is 
still being used by many investigators. Therefore, 
because the optimized spectrophotometric HMG-
CoA reductase activity assay presented here is 
based on rat liver microsomes, it offers a new 
alternative for assessing tissue-derived whole 
protein, which would be valuable for investigating 
cholesterol metabolism in liver tissue. In addition, 
by using different enzyme sources (i.e. 
commercial human or animal microsomes), this 
improved method could also be used to screen 
candidate HMG-CoA reductase inhibitors in a 




An improved spectrophotometric HMG-CoA 
reductase activity assay has been successfully 
developed by optimizing different variables 
relating to the reaction conditions, including 
preincubation of the enzyme and cofactor prior to 
HMG-CoA addition. This optimal method is rapid, 
simple and relatively low cost. It overcomes the 
low specificity and sensitivity associated with 
existing spectrophotometric methods, while 
maintaining a relatively high HMG-CoA 
reductase activity and greatly increasing 
hypolipidemic agent screening efficiency. 
Therefore, this improved spectrophotometric 
assay provides an alternative technique for 
studying cholesterol metabolism and favorable 
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